Multimodal R&D Management with Incyte's Jim Lee, M.D., Ph.D.

Business Of Biotech

We love to hear from our listeners. Send us a message.

Success at multimodal, multi-indication, deep-pipelined Incyte—where commercial operations are as familiar as pre-discovery activity is—begins at the earliest opportunity to achieve research and discovery efficiencies. The company’s a bit larger than those we typically cover on the Business of Biotech, and that’s okay! Sometimes, the smartest approach to creating your own masterpiece is to study the masters On this episode of the podcast, we sit down with Incyte’s Group Vice President and head of its Inflammation and AutoImmunity Group, Jim Lee, M.D., Ph.D. for a dissection of the company’s approach to the comprehensive and efficient R&D that leads to repeated clinical and commercial success.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

Kapitler

1. Managing R&D and Biotech Progress (00:00:00)

2. Emotional Investment and Data-Driven Decision Making (00:13:02)

3. Insight Dermatology and Recruitment Process (00:21:39)

4. Impact of Platforms in Biotech (00:29:19)

5. Insight's Dermatology Pipeline and Future Plans (00:41:03)